Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety

{{article.zuoZheEn}}

PDF(636 KB)
PDF(636 KB)
Front. Med. ›› 2019, Vol. 13 ›› Issue (3) : 344-353. DOI: 10.1007/s11684-018-0639-7
RESEARCH ARTICLE

Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety

  • {{article.zuoZheEn}}
Author information +
History +

Highlights

{{article.highlightEn}}

Abstract

{{article.abstractEn}}

Author summary

{{article.authorSummayEn}}

Keywords

Cite this article

Download citation ▾
{{article.zuoZheEn_L}}. {{article.titleEn}}. Front. Med., 2019, 13(3): 344‒353 https://doi.org/10.1007/s11684-018-0639-7

References

References

{{article.reference}}

RIGHTS & PERMISSIONS

{{article.copyright.year}} {{article.copyright.holder}}
Share on Mendeley
PDF(636 KB)

Accesses

Citations

Detail

Sections
Recommended

/